ALTIMMUNE, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ALTIMMUNE, INC. (ALT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $4.09 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- ALTIMMUNE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $4.52, a 32.64% decline year-over-year.
- ALTIMMUNE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $6.71, a 28.00% decline year-over-year.
- ALTIMMUNE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $9.32.
- ALTIMMUNE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $5.21, a 40.32% decline from fiscal 2024.
- ALTIMMUNE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $8.73, a 10.09% decline from fiscal 2023.
- ALTIMMUNE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $9.71, a 14.50% increase from fiscal 2022.
- ALTIMMUNE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $8.48, a 40.86% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.09 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $4.52 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $5.21 10-K · filed 2026-03-06 | |||
| 2025-09-30 | $5.86 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $6.61 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $6.71 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $8.73 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $8.96 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $9.32 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $9.32 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $9.71 10-K · filed 2024-03-27 | |||
| 2022-12-31 | $8.48 10-K · filed 2023-02-28 | |||
| 2021-12-31 | $14.34 10-K · filed 2022-03-15 | |||
| 2020-12-31 | $4.75 10-K · filed 2021-02-25 | |||
| 2019-12-31 | $2.67 10-K · filed 2020-03-27 | |||
| 2018-12-31 | $4.63 10-K · filed 2019-04-01 | |||
| 2017-12-31 | $3.03 10-K · filed 2018-04-02 | |||
| 2012-12-31 | $1.22 10-K · filed 2013-03-14 | |||
| 2011-12-31 | $1.71 10-K · filed 2013-03-14 | |||
| 2010-12-31 | $2.50 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |